University of Toledo Medical Center, Toledo, OH 43614, USA.
Int Urol Nephrol. 2013 Aug;45(4):1219-22. doi: 10.1007/s11255-012-0146-8. Epub 2012 Apr 3.
Primary CNS lymphoma (PCNSL) is a rare B cell variant non-Hodgkins lymphoma that is confined to the brain, leptomeninges, spinal cord and eyes. Its incidence is increasing, primarily due to increase in the number of organ transplantations being undertaken. The majority of the PTLD (post-transplant lymphoproliferative disorder) is seen in kidney transplant recipients simply because they constitute a larger group of transplant recipients each year as compared to other solid organ transplantations. Primary infection of previously infected EBV seronegative patients and immunosuppression are found to be the main etiologic factors in the development of PTLD-PCNSL. There are no clear guidelines on treatment regimens, and it should be individualized according to patient comorbidities. We report a case of PCNS lymphoproliferative disorder in a kidney transplant recipient, which underwent complete remission with decreasing immunosuppression. The patient could not undergo chemotherapy/radiotherapy due to underlying comorbidities. We highlight the available treatment modalities for PTLD-PCNSL.
原发性中枢神经系统淋巴瘤（PCNSL）是一种罕见的 B 细胞变异型非霍奇金淋巴瘤，局限于大脑、软脑膜、脊髓和眼睛。其发病率正在增加，主要是由于器官移植数量的增加。大多数移植后淋巴组织增生性疾病（PTLD）见于肾移植受者，仅仅是因为与其他实体器官移植相比，每年他们构成了更大的移植受者群体。先前感染 EBV 血清阴性的患者的原发性感染和免疫抑制被认为是导致 PTLD-PCNSL 的主要病因。目前尚无关于治疗方案的明确指南，应根据患者的合并症进行个体化治疗。我们报告了一例肾移植受者的 PCNS 淋巴组织增生性疾病，该患者通过降低免疫抑制实现完全缓解。由于潜在的合并症，该患者无法进行化疗/放疗。我们强调了 PTLD-PCNSL 的可用治疗方法。
